

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

BUSINESS UPDATE PRODUCT COOPERATION AGREEMENTS

The board of directors (“Board”) of Dawnrays Pharmaceutical (Holdings) Limited (the “Company”) is pleased to announce that its wholly-owned subsidiary Suzhou Dawnrays Pharmaceutical Co., Ltd.* 蘇州東瑞製葯有限公司 (“Suzhou Dawnrays Pharma”), has entered into product cooperation agreements to engage Nanjing Han Xin Pharmaceutical Technology Co., Ltd.* 南京漢欣醫葯科技有限公司 (“Nanjing Han Xin”), an independent third party, to carry out the research and development of the following products (“Products”) and assist Suzhou Dawnrays Pharma to obtain the marketing authorisation holder (MAH) status for the Products: -

- (a) Z2101 and Z2102 – Z2101 is a single use prefilled syringes for injection and Z2102 is ampoules for injection. Both drugs are for using in blood and hematopoietic system to prevent and treat bleeding.
- (b) Z2103 – It is a synthetic polypeptide hormone, the 1-34 amino acids fragment of parathyroid hormone (PTH), packed in multi-dose prefilled pens for injection for the treatment of osteoporosis.
- (c) H2104 and Z2105 – An active pharmaceutical ingredient and packed in multi-dose prefilled pens for injection for assisted reproduction. It is a synthetic polypeptide, and Gonadotropin-releasing hormone (GnRH) antagonist.
- (d) Z2106 – It is a synthetic form of long-acting Glucagon-Like Peptide-1 (GLP-1) Analogues, packed in multi-dose prefilled pens for injection for the treatment of diabetes.

Suzhou Dawnrays Pharma has engaged in research and development, manufactures and sales of system specific medicines mainly in oral forms covering therapeutic fields of hypertension, lipid-regulation, anti-allergic, anti-HBV, and gout treatment. It is expected that the engagement will expand the range of products to both oral and injectable forms offered by the Group for patients in chronic conditions.

Z2101 and Z2102 are complex injectables. There is no similar products that have passed consistency evaluation in mainland China as at the date of this announcement. Z2101 is proposed for research and development to meet domestic clinical needs of neonatal patients with related diseases.

The Z2103, Z2105 and Z2106 are polypeptide therapeutics. In China, the market for such polypeptide therapeutics, in particular the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, is dominated by foreign manufacturers. Domestic products are mainly in the phase of introduction and development. It is expected that there will be great potential for locally manufactured products in the PRC market.

With China's aging population, it is expected that there will be increase in demand for treatment for chronic diseases such as diabetes and osteoporosis, including high-quality, safe, patient self-administered injectables. With the engagement of Nanjing Han Xin, the Group may develop a series of polypeptide therapeutics with drug delivery system using injectable pens for diabetes and osteoporosis fields, which in turn may in the long run improve the Group's market competitiveness.

The Board considers that the engagement with Nanjing Han Xin can enhance the Group's capability in offering differentiated generic drugs in the field of chronic diseases, which is in line with the company's development strategy and are in the interests of the Company and its shareholders as a whole.

By Order of the Board of
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 23 September 2021

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

** for identification purpose only*